Ophthalmic manifestations of HIV infection KRISADA HANBUNJERD.

Slides:



Advertisements
Similar presentations
Evan (Jake) Waxman MD PhD
Advertisements

Debilitating Eye Diseases
DIABETIC RETINOPATHY Diabetic retinopathy is a frequent cause of blindness. The exact cause of diabetic microvascular disease is unknown.
21/4/ Pegaptanib Sodium ( MACUGEN) for Macular Edema Secondary to Central Retinal Vein Occlusion Mahmood J Showail.
Dr Mahmood Fauzi ASSIST PROF OPHTHALMOLOGY AL MAAREFA COLLEGE
Clinicopathologic Case
DIABETIC RETINOPATHY.
Dr Mahmood Fauzi ASSIST PROF OPHTHALMOLOGY AL MAAREFA COLLEGE
Systemic diseases and Eye diseases The 4th Affilitated Hospital of China Medical University Eye Hospital of China Medical University.
Wednesday AM report Uveitis and Cogan’s syndrome.
Retinal Anatomy Dr. Miratashi.
Age-Related macular degeneration & retinitis pigmentosa Ayesha S abdullah
Diabetic Retinopathy Steven Sanislo, M.D. Assistant Professor Stanford University Department of Ophthalmology.
Cytomegalovirus DR.K.RAJA GHTM CHENNAI
Vitrasert Ganciclovir Intraocular Implant This is a reservoir style implant used for the delivery of the anti-viral drug ganciclovir to treat AIDs-related.
The Canadian Association of Optometrists
Barrow, Brantley, Fredde, Gillispie
New Treatment Opportunity: Valganciclovir
Orbit 2 Orbital infections Dr. Mohammad Shehadeh.
3.04 Functions and disorders of the eye
Sclera/Episclera, Uvea/Iris, Vitreous, & Glaucoma.
HERPES SIMPLEX ENCEPHALITIS ENCEPHALITIS M.RASOOLINEJAD, MD DEPARTMENT OF INFECTIOUS DISEASE TEHRAN UNIVERCITY OF MEDICAL SCIENCE.
Dr mahmood fauzi ASSIST PROF OPHTHALMOLOGY AL MAAREFA COLLEGE.
Neuro-ophthalmology Dr. Abdullah Al-Amri Ophthalmology Consultant.
Updates on Optic Neuritis Briar Sexton Neuro-ophthalmology Clinical Day Friday, November 18, 2005.
Acute and Chronic visual loss By Dr. ABDULMAJID ALSHEHAH Ophthalmology consultant Anterior Segment and Uveitis consultant.
Antiviral Drugs Prof. Alhaider, 1431 H Definition: Viral infections depend on the host cells. Therefore, antiviral drugs must block viral entry or exit.
Connie van Marrewijk IDA Foundation Product Selection for Opportunistic Infections.
Vitrasert Ganciclovir Intraocular Implant Reservoir style implant used for the delivery of the anti-viral prodrug ganciclovir. Vitrasert was the first.
Ocular Manifestations of Systemic Diseases Dalman.
Josephine Carlos-Raboca, M.D. Makati Medical Center
Prophylaxis of Opportunistic Infections
After Cataract Surgery…
Debra Goldstein, MD Northwestern University Chicago, IL
Ahmed Y. Hatata, MSc Rowayda M. Amin, MSc Assistant Lecturer Ophthalmology Alexandria University, Egypt Toxocariasis.
CMV Retinitis Rupesh Agrawal, Carlos Pavesio Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.
ACUTE RETINAL NECROSIS
Tubulointerstitial Nephritis and Uveitis (TINU) Syndrome Sana Khochtali Imen Ksiaa Anis Mahmoud Bechir Jelliti Department of Ophthalmology Fattouma Bourguiba.
Centre of Ophthalmology University of Tuebingen, Germany
Manfred Zierhut Manfred Zierhut Centre of Ophthalmology University of Tuebingen, Germany Masquerade Syndrome.
SPOT DIAGNOSIS DARINDA ROSA R2.
Dr. G. Rajasekhar D.N.B, FRCS
Toxoplasmic Retinochoroiditis Rupesh Agrawal, Carlos Pavesio Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.
BRVO. Present by Sattar Heidari MD General ophthalmologist.
Corticosteroid-induced central serous chorioretinopathy in patients with Ocular Toxoplasmosis Merih Soylu, MD, Prof. Ophthalmology, Füsun Uzunoğlu, MD.
DR TRUPTI SHARMA CONSULTANT & PHACOSURGEON DR OM PARKASH EYE INSTITUTE.
Hypopyon Uveitis Linda Huang, MD Ronald Rescigno, MD Rutgers, New Jersey Medical School.
The anatomy of the orbit
OCULAR MANIFESTATIONS OF SARCOIDOSIS
Ocular Complications of AIDS: Learning from the Past John H. Kempen, M.D., Ph.D. Co-Founder and President, Sight for Souls Professor of Ophthalmology and.
Eye Manifestation in systemic disease
HYPERTENSIVE RETINOPATHY
Systemic disease in ophtlhalmology
Posterior Uveitis Mehmet Can ERATA.
Systemic Diseases.
Assessing The Eyes DR. ALI ALIBRAHIMI M.B.Ch.B ASSESSING THE EYES.
Varicella-zoster necrotising retinitis with panuveitis following uncomplicated chickenpox in a seemingly immune competent child S Chamney1, J Yu1, S Hughes2,
UVEAL INFECTIONS AND INFESTATIONS
Differential Diagnosis I:
Anatomy of the Eye III: correlations with clinical exam and diagnosis
THERAPY FOR UVEITIS. THERAPY FOR UVEITIS OBSERVATION For development of complications For change in the appearance / severity/progression.
Inflammatory Chorioretinopathies of Unknown Etiology
January 16, 2019.
Management of Immune Reconstitution Inflammatory Syndrome (IRIS)
Important notes by the doctor
Presentation transcript:

Ophthalmic manifestations of HIV infection KRISADA HANBUNJERD

ophthalmic manifestation of HIV infection2 Ophthalmic manifestations Incidence = 44.6%* consist of  Noninfectious microangiopathy  Opportunistic ocular infections  Neoplasm of ocular adnexa  Neuroophthalmic manifestation  Drug-induced manifestation *epidemiology of ocular complication of HIV infection in ChiangMai

ophthalmic manifestation of HIV infection Noninfectious microangiopathy  Conjunctival vessel abnormalities capillaries dilatation isolated vascular fragment irregular vessel caliber granular blood column  HIV retinopathy

ophthalmic manifestation of HIV infection4 HIV retinopathy overview  most common ophthalmic lesion  characterized by cotton wool spot retinal hemorrhage microaneurysm telangiectatic vessel  indicate immune deteriolation

ophthalmic manifestation of HIV infection HIV retinopathy manifestations Cotton Wool Spot occur 28-92% of patient with AIDS are microinfarct of nerve fiber layer of retina clinically white fluffy lesion with feathery border common site is peripapilla resolved within 4-6 weeks Retinal Hemorrhage occur less than 20% Perivascular Sheathing occur less than 1% more common in AFRICA

ophthalmic manifestation of HIV infection6 HIV retinopathy pathogenesis  multifactorial  may be immune complex deposition HIV infection of retinal vascular endothelium local release of cytotoxic factors rhealogic abnormalities such as RBC aggregation,elevated fibrinogen level circulating immune complex,plasma viscosity

ophthalmic manifestation of HIV infection Differentiation  Diabetes Mellitus  Malignant Hypertension  Collagen Vascular Disease

ophthalmic manifestation of HIV infection8 Differentiation  especially from early Cytomegalovirus Retinitis

ophthalmic manifestation of HIV infection Opportunistic ocular infections (COMMON)  Anterior segment Microsporidial keratoconjunctivitis Herpes zoster ophthalmicus eyelid Molluscum contagiosum

ophthalmic manifestation of HIV infection10 Opportunistic ocular infections (COMMON)  Posterior segment Cytomegalovirus retinitis Varicella zoster retinitis Toxoplasma retinitis

ophthalmic manifestation of HIV infection Opportunistic ocular infections (UNCOMMON)  Anterior segment Bacterial keratitis Herpes simplex keratitis  Posterior segment Pneumocystic choroiditis Fungal chorioretinitis Ocular syphilis Ocular tuberculosis

ophthalmic manifestation of HIV infection12 Cytomegalovirus Retinitis overview  The most common of opportunistic ocular infection in patient with AIDS  occur in approximately 20-40% of these patient  progressive if left untreated  potentially blinding disease  ultimately developed bilateral

ophthalmic manifestation of HIV infection13 Cytomegalovirus Retinitis High Risk  CD Count < 50  Associated with PCP, Extraocular CMV,Toxoplasmosis  HLA B44, B51, DR7

ophthalmic manifestation of HIV infection14 Cytomegalovirus Retinitis Symptoms  asymptomatic  light flash  floater  visual field loss  blurred or distorted vision  red eye,eye pain,photophobia are rare

ophthalmic manifestation of HIV infection15 Cytomegalovirus Retinitis Signs  no conjunctival hyperemia  minimal anterior chamber inflammatory reaction  minimal vitreous inflammatory reaction  typically yellow to white area of retinal necrosis that follow a vascular distribution

ophthalmic manifestation of HIV infection16 Cytomegalovirus Retinitis Diagnosis based on  clinical fundus appearance  vitreous and aqueous humor analysis for CMV DNA **  endoretinal biopsy ** ** for atypical presentation or unresponsive to treatment (usually not be done in normal setting)

ophthalmic manifestation of HIV infection17 Cytomegalovirus Retinitis Clinical Presentation Spectrum of fundus appearance  fulminant/edematous form  indolent form  frosted branch angiitis form  atypical form

ophthalmic manifestation of HIV infection18 Cytomegalovirus Retinitis Clinical Presentation Fulminant form  dense confluent area of retinal opacification  location along vesseles  no clear central atrophic area  sufficient retinal hemorrhage  inflammatory perivascular sheathing

ophthalmic manifestation of HIV infection19 Cytomegalovirus Retinitis Clinical Presentation Indolent form  faint grainy opacification or blush fire  location not overlying vessel  may have central clear atrophic area  no or minimal retinal hemorrhage  no inflammatory vascular sheathing

ophthalmic manifestation of HIV infection20 Cytomegalovirus Retinitis Clinical Presentation Frosted branch angiitis form  usually neglected case  indicate insufficient control of disease ( practically seen in patient who lost follow up treatment)

ophthalmic manifestation of HIV infection21 Cytomegalovirus Retinitis Systemic Treatment FDA approved  IV Gancyclovir Induction and Maintenance  IV Foscarnet Induction and Maintenance  IV Gancyclovir Induction and Oral Gancyclovir Maintenance  IV Cidafovir Induction and Maintenance  Oral valgancyclovir for Induction and Maintenance (non zone1CMVR)

ophthalmic manifestation of HIV infection22 Retinal Zone

ophthalmic manifestation of HIV infection23 Cytomegalovirus Retinitis Dosage Gancyclovir IV Dosage  Induction 5mg/kg q 12 hours days  Maintenance 5mg/kg daily or 6mg/kg 5 out of 7 days Foscarnet IV Dosage  Induction 60 mg/kg q 8 hours days  Maintenance mg/kg daily

ophthalmic manifestation of HIV infection24 SOCA1  234 patients with newly diagnosed CMVR randomized to gancyclovir or foscarnet  Time to progression :56 days for gancyclovir V.S. 59 days for foscarnet (p=0.685)  Median survival 12.6 months for foscarnet V.S. 8.5 months for gancyclovir

ophthalmic manifestation of HIV infection25 SOCA1  More neutropenia with gancyclovir  More infusion related symptoms genitourinary symptoms,nephrotoxic effect and electrolyte abnormality with foscarnet  Patient with foscarnet more likely to be switched to alternative treatment (46% V.S. 11%;p<0.00)  Toxicity resolved in 88% of cases after treatment switches

ophthalmic manifestation of HIV infection26 Cytomegalovirus Retinitis Dosage Cidofovir IV Dosage  Induction 5mg/kg weekly 2 weeks  Maintenance 5mg/kg every 2 weeks

ophthalmic manifestation of HIV infection27 Cytomegalovirus Retinitis General Consideration of Treatment  IV Antivirals are all effective for induction and maintenance  IV Antivirals have unique complications gancyclovir-neutropenia foscarnet-nephrotoxic cidofovir-nephrotoxic,uveitis,hypotony

ophthalmic manifestation of HIV infection28 Cytomegalovirus Retinitis General Consideration of Treatment(continue)  IV Treatment is associated with catheter’s complication  IV Treatment is costly  IV Treatment needs hospitalization?  Time consumed  Systemic or Local Treatment

ophthalmic manifestation of HIV infection29  Intravitreal drugs Gancyclovir Foscarnet Cidofovir fomivirsen  Gancyclovir Intraocular Implant Cytomegalovirus Retinitis Local Treatment

ophthalmic manifestation of HIV infection30 Cytomegalovirus Retinitis Intravitreal Injection Gancyclovir Dosage  Induction : microgram 2-3times/week  Maintenance: same dose weekly Foscarnet Dosage  Induction mg 2 times/week  Maintenance mg weekly Cidofovir Dosage  20 microgram q 5-6 weeks

ophthalmic manifestation of HIV infection31 Cytomegalovirus Retinitis Intravitreal Injection

ophthalmic manifestation of HIV infection32 Cytomegalovirus Retinitis Gancyclovir Implant

ophthalmic manifestation of HIV infection33 Cytomegalovirus Retinitis Gancyclovir Implant  release drug 1 microgram/hour for 32 weeks  intravitreal drug level 4 fold higher than intravenous  median time to progress = 226 days  retinal detachment 11-23%  contralateral involvement 50% in 6 months

ophthalmic manifestation of HIV infection34 CYTOMEGALOVIRUS RETINITIS Local Treatment(advantages)  prevent systemic side effect  need less drug so less cost  improve quality of life  higher drug concentration

ophthalmic manifestation of HIV infection35 Intraocular Gancyclovir Level microgram/ml  intravenous induction0.78  intravenous maintenance0.63  oral gancyclovir0.83  implant4  intravitreal injection(24hr)143  intravitreal injection(72hr)23

ophthalmic manifestation of HIV infection36 CYTOMEGALOVIRUS RETINITIS Local Treatment(disadvantages)  unability to protect contralateral eye  increase risk of extraocular CMVR  less survival

ophthalmic manifestation of HIV infection37 CYTOMEGALOVIRUS RETINITIS Local Treatment(complications)  increase intraocular pressure  increase risk of retinal detachment  vitreous hemorrhage  endophthalmitis  scarring of injected site,retinal toxicity?

ophthalmic manifestation of HIV infection38 Role of oral Gancyclovir  Low bioavailability  Cause neutropenia  Not indicate for induction therapy*  Suitable for maintenance therapy in higher dose (>4500mg/day)*  May be combined with IV Gancyclovir or Gancyclovir implant *due to low intraocular gancyclovir level

ophthalmic manifestation of HIV infection39 valgancyclovir (valcyte)  is an L-valyl ester (prodrug) of ganciclovir  absolute bioavailability was approximately 60%  rapid conversion to ganciclovir  elimination by renal excretion through glomerular filtration and active tubular secretion.  The half-life (t 1/2 ) of ganciclovir following oral administration of valganciclovir tablets was hours (n=73)

ophthalmic manifestation of HIV infection40 Dosage of Valgancyclovir  Dose Modifications for Patients with Impaired Renal Function  CrCl(mL/min)Induction DoseMaintenance Dose  > mg twice daily900 mg once daily  40 – mg twice daily450 mg once daily  25 – mg once daily450 mg every 2 days  10 – mg every 2 days450 mg twice weekly

ophthalmic manifestation of HIV infection41 Comparison of Valgancyclovir and IV,Oral Gancyclovir

ophthalmic manifestation of HIV infection42  Decrease incidence From 21.9 Per 100 Person-Year To 3.7 Per 100 Person-Year  Change in the clinical course of the disease  Altered Clinical presentation CYTOMEGALOVIRUS RETINITIS IN HAART ERA

ophthalmic manifestation of HIV infection43 CLINICAL COARSE CHANGE  From Progressive if lefted untreated  To Ability to discontinue AntiCMV agent without progression

ophthalmic manifestation of HIV infection44

ophthalmic manifestation of HIV infection45 ALTERED CLINICAL PRESENTATION FROM IMMUNE RESTORATION  Immune Recovery Vitritis  Cystoid Macula Edema  Epiretinal Membrane  Vitreomacula traction syndrome  Disc Edema and Neovascularization

ophthalmic manifestation of HIV infection46 IMMUNE RECOVERY UVEITIS(IRU)  3 I  Intraocular inflammation characterized by vitritis,disc edema, cytoid macula edema usually reversible, treated by local steroid if still unchanged  Inactive cytomegalovirus retinitis  Immune recovery by CD4 rise >50 longer than 3 months

ophthalmic manifestation of HIV infection47 IMMUNE RECOVERY VITRITIS

ophthalmic manifestation of HIV infection48 D/D for CMVR  Progressive Outer Retinal Necrosis  Toxoplasma Retinitis  Intraocular Lymphoma  Ocular Syphilis

ophthalmic manifestation of HIV infection49 Progressive Outer Retinal Necrosis  caused by VZV, Herpes simplex virus, CMV  minimal anterior and vitreal inflammatory reaction  start at peripheral retina first as deep multifocal opacification  then progress rapidly to posterior pole and cause secondary retinal detachment finally

ophthalmic manifestation of HIV infection50 Toxoplasmic Retinitis  usually acquired disease  granulomatous anterior uveitis  focal or multifocal retinitis +/- vitritis  no previous toxoplasma retinochoroidal scar  approximately 50% of retinitis patient have encephalitis (not vice verca)

ophthalmic manifestation of HIV infection51 Neoplasm of Ocular Adnexa  Kaposi sarcoma usually asymptomatic sites involved are eyelid, conjunctiva, orbit inferior fornix is most common site  non Hodkin’s lymphoma non tender anterior orbital mass proptosis, diplopia, ptosis, eyelid edema  Conjunctival squamous carcinoma

ophthalmic manifestation of HIV infection52 Neuroophthalmic Manifestations  Cranial nerve palsy: CN6 palsy Internuclear ophthalmoplegia CN 3 palsy  Visual field defects

ophthalmic manifestation of HIV infection53 Neuroophthalmic Manifestations  Optic nerve disorder Papilledema, optic atrophy retrobulbar optic neuritis papillitis  Cortical blindness

ophthalmic manifestation of HIV infection54 Cryptococcal Papilledema  cause increase intracranial pressure back to the eye  these picture show optic nerve head in various stage

ophthalmic manifestation of HIV infection55 Drug induced manifestations  Cidofovir anterior uveitis, hypotony,enopthalmos

ophthalmic manifestation of HIV infection56 Drug induced manifestations  Rifabutin anterior uveitis  Terbinafine anterior uveitis, iridodonesis phacodonesis, conjunctival hemorrhage

ophthalmic manifestation of HIV infection57 International Variation of Manifestations most common reported ocular conditions  Industrialized Countries  Subsaharan Africa  Latin America  South and Southeast Asia  CMVR  HZO conjunctival squamous cell tumors  CMVR ocular toxoplasmosis  CMVR HZO

QUESTION

ophthalmic manifestation of HIV infection59 Do Not Miss Unseen Thailand

Thanks for Your Attentions